TRBV20-1: A Promising Drug Target and Neuroprotective Peptide

Target Name: TRBV20-1

NCBI ID: G28567

TRBV20-1

Other Name(s): TCRBV20S1 | T cell receptor beta variable 20-1 | TRBV201 | TCRBV2S1

TRBV20-1: A Promising Drug Target and Neuroprotective Peptide

TRBV20-1 (TcRBV20S1) is a synthetic peptide derived from the extracellular domain of the protein TRPV2 (Transient receptor potential cation channel subfamily 2 member 1). TRPV2 is a G protein-coupled receptor that plays a role in mediating pain, inflammation, and other physiological processes in the body. The TRPV2 gene has been implicated in the development of various diseases, including neuropathic pain, migraine, and chronic pain.

TRBV20-1 is a small peptide that consists of 20 amino acid residues. It is highly conserved, with a high degree of sequence identity to TRPV2. The peptide has been shown to have potent analgesic, anti-inflammatory, and neuroprotective properties in animal models of pain and neurodegenerative diseases.

One of the unique features of TRBV20-1 is its ability to cross the blood-brain barrier and its high affinity for TRPV2. This allows the peptide to efficiently reach the target protein TRPV2 in the brain and spinal cord, where it can modulate the activity of TRPV2 to produce its effects.

In pain research, TRBV20-1 has been shown to be a potential drug target for the treatment of neuropathic pain, migraine, and other chronic pain conditions. Studies have shown that TRBV20-1 can effectively alleviate pain in animal models of neuropathic pain, including pain caused by thermal, chemical, and mechanical stimuli.

In addition to its potential use as a pain medication, TRBV20-1 has also been shown to have neuroprotective properties. Studies have shown that TRBV20-1 can protect against neurotoxicity in rat cerebral cortical neurons, indicating that it may have a neuroprotective effect on the brain. This may be useful for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Another potential application of TRBV20-1 is its use as a biomarker for the diagnosis and monitoring of neurodegenerative diseases. The peptide has been shown to be effective in detecting neurodegeneration in animal models of neurodegenerative diseases, including dopamine neuron loss in Parkinson's disease and amyloid neuroinclusion in Alzheimer's disease.

In conclusion, TRBV20-1 is a promising drug target and biomarker for the treatment of neuropathic pain, neurodegenerative diseases, and other chronic pain conditions. Its ability to cross the blood-brain barrier and its high affinity for TRPV2 make it an attractive candidate for drug development. Further research is needed to fully understand the potential of TRBV20-1 as a therapeutic agent and to develop safe and effective treatments for neuropathic pain and neurodegenerative diseases.

Protein Name: T Cell Receptor Beta Variable 20-1

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV20-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV20-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets